Long-Term Persistence of Anti-SARS-CoV-2 Antibodies in a Pediatric Population.
Pathogens
; 10(6)2021 Jun 04.
Article
in English
| MEDLINE | ID: covidwho-1259561
ABSTRACT
BACKGROUND:
Antibody dynamics over time after SARS-CoV-2 infection are still unclear, and data regarding children are scarce.METHODS:
A prospective cohort study was performed including children infected by SARS-CoV-2 between March and May 2020. Patients were categorized into 3 groups children admitted with COVID-19; outpatient children with mild COVID-19; and seropositive children participating in a seroprevalence study among cohabitants of infected healthcare workers (HCWs). Six months after the infection, a new serological control was performed.RESULTS:
A total of 58 children were included, 50% male (median age 8.3 [IQR 2.8-13.5] years). The median time between the two serological studies was 186 (IQR 176-192) days, and 86% (48/56) of the children maintained positive IgG six months after the infection. This percentage was 100% in admitted patients and 78% among the rest of the included children (p = 0.022). The diagnoses of lower respiratory tract infection and multisystemic inflammatory syndrome were associated with persistence of IgG (p = 0.035). The children of HCWs in the seroprevalence study lost antibodies more often (p = 0.017). Initial IgG titers of the children who remained positive six months after the infection were significantly higher (p = 0.008).CONCLUSIONS:
Most children infected by SARS-CoV-2 maintain a positive serological response six months after the infection. Those children who lost their IgG titer were more frequently asymptomatic or mildly symptomatic, presenting with low antibody titers after the infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Pathogens10060700
Similar
MEDLINE
...
LILACS
LIS